EGFR and non-small cell lung carcinoma: EGFR‐TKIs can prolong patients’ progression free survival and overall survival in NSCLC clinical treatment, especially in relatively sensitive patients, both in one‐line and multi‐line treatment and the side effects are mild.4 However, there is no significant effect of EGFR‐TKs on some patients, EGFR mutations for example; or patients initially sensitive to EGFR‐TKIs with good efficacy for some time (about 1‐1.5 years), but subsequently prone to develop disease progression and EGFR‐TKI resistance, the so‐called secondary resistance.5